Co-Diagnostics, Inc. reports developments in molecular diagnostics, including its patented platform for designing molecular diagnostic tests and its Co-Dx PCR platform. Company news commonly covers clinical and regulatory disclosures, commercialization activity through CoSara and CoMira joint ventures, intellectual property and technology updates, and operating and financial results.
Recurring updates also include material agreements, governance matters, capital-structure actions, and securities-listing developments. The company’s public disclosures connect its diagnostic-test pipeline, platform development, and commercialization strategy with financing, shareholder approvals, and other corporate actions.
Co-Diagnostics, Inc. reported its First Quarter 2024 Financial Results, showcasing a revenue of $0.5 million, down from $0.6 million in the prior year. Operating expenses increased by 4.4% due to research and development costs. The company reported an operating loss of $10.3 million and a net loss of $9.3 million. Adjusted EBITDA loss was $8.4 million. Co-Diagnostics highlighted key business highlights, including new executive appointments and facility expansions in Salt Lake and India. The company is focused on FDA submissions for new products and continued test development for various conditions.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.